Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
Overview
AngioDynamics Inc is a Nasdaq-listed public company renowned for designing, manufacturing, and selling a broad portfolio of innovative medical devices that serve diverse clinical applications. With deep expertise in the fields of oncology, interventional radiology, and vascular surgery, the company focuses on the minimally invasive treatment of diseases such as peripheral vascular disorders and cancer. Industry-specific keywords such as "minimally invasive procedures", "diagnostic devices", and "interventional radiology" underscore the company’s commitment to technological innovation.
Core Business and Operations
The company operates by providing a comprehensive range of devices which include systems for radiofrequency ablation, vascular access, angiographic procedures, dialysis support, angioplasty, drainage, thrombolysis, embolization, and venous treatments. These products are designed for use in clinical settings by interventional radiologists, surgeons, and nephrologists. Through its diverse product line, AngioDynamics is able to offer end-to-end solutions that enhance procedural efficiency and patient outcomes. The revenue model primarily relies on direct sales to healthcare institutions, supported by a strong service network ensuring reliability and continued product support.
Market Position and Competitive Landscape
AngioDynamics has distinguished itself in a technologically competitive and high-growth industry. By investing in research and development, the company has maintained its ability to continuously bring forward new technologies and improve existing products. This commitment to innovation positions the company among notable competitors in the medical device industry. Its competitive differentiation stems from a consistent track record of product innovation, robust clinical performance, and strategic market presence. The company's market position is further bolstered by its focused approach to addressing specialized clinical needs and its ability to integrate advanced technological solutions into traditional treatment paradigms.
Product Portfolio and Technological Innovation
The product portfolio of AngioDynamics spans a wide range of medical device categories. From advanced radiofrequency ablation systems to precision surgical tools, the company leverages cutting-edge technology to develop devices that offer improved safety profiles and enhanced procedural outcomes. Emphasis on 'innovative technology' and 'minimally invasive procedures' highlights the company’s pursuit of excellence in device performance. Each product category is built on comprehensive clinical insights and a deep understanding of procedural requirements, ensuring that healthcare providers are equipped with devices that cater to their diagnostic and therapeutic needs.
Operational Excellence and Industry Expertise
AngioDynamics demonstrates operational excellence by aligning its product development with the evolving needs of healthcare providers. The company’s strategic focus on clinical innovation and rigorous quality control reflects its deep industry expertise and commitment to delivering reliable and effective medical solutions. Structured research programs, continuous product improvements, and a robust post-market support system underpin the company’s reputation for innovation and operational excellence. This integrated approach assists healthcare professionals in achieving improved outcomes while ensuring safety and compliance under constantly evolving medical standards.
Strategic Business Model and Value Proposition
Central to AngioDynamics' value proposition is the delivery of solutions that advance the standard of care in critical clinical procedures. The company’s business model is built around the continuous enhancement of product performance and the facilitation of minimally invasive therapeutic options. By maintaining a deep focus on quality and usability, AngioDynamics provides a reliable partnership for medical institutions seeking to integrate innovative device technologies. This strategic alignment with frontline clinical needs makes the company a noteworthy reference point for discussions on medical innovation, procedural efficiency, and enhanced patient care.
Industry Impact and Long-Term Relevance
With a rich history dating back to its founding in 1988, AngioDynamics has consistently contributed to medical advancements through its innovative product solutions. The company's impact on the healthcare industry is visible across multiple clinical areas, reinforcing its role as a significant player in medical technology. The enduring relevance of its products and the clarity of its market focus ensures that AngioDynamics remains a principal component in the discussion of medical device innovation and procedural technology. This comprehensive approach, combined with clear communication and expert-driven design, continues to shape the narrative around modern, efficient, and effective clinical practices.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its third-quarter fiscal year 2022 financial results on April 7, 2022, before market opening. A conference call hosted by management will commence at 8:00 a.m. ET on the same day, allowing investors to discuss the financial outcomes. Participants can join the call via phone or access the live webcast from the AngioDynamics website. The call's recording will be available for playback shortly after its conclusion. AngioDynamics specializes in innovative, minimally invasive medical devices for various healthcare applications.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that President and CEO Jim Clemmer and CFO Stephen Trowbridge will present at three investor conferences in March 2022. The conferences include:
- Oppenheimer Virtual Healthcare Conference: March 15, 2022, at 8:40 a.m. ET
- Barclays Global Healthcare Conference: March 16, 2022, in Miami Beach, FL, at 9:00 a.m. ET
- KeyBanc Virtual Life Sciences & MedTech Investor Forum: March 22, 2022, at 3:45 p.m. ET
Live webcasts will be available on the company's website.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 10:00 a.m. ET. This event is designed for BTIG clients. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse product line including ablation systems and vascular access products. For more details, visit www.angiodynamics.com.
AngioDynamics reported fiscal Q2 2022 net sales of $78.3 million, up 7.6% year-over-year. Med Tech sales surged 36.4%, while Med Device grew 0.8%. Gross margin declined to 51.8%, impacted by a $4 million backlog due to ongoing supply chain challenges. The company recorded a GAAP loss per share of $0.21 and an adjusted loss of $0.02. Full market release of the AlphaVac device occurred post-quarter. Fiscal year 2022 revenue guidance remains at $310-315 million, but gross margin guidance was revised down to 52.0%-54.0%.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 24th Annual Needham Virtual Growth Conference on January 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast through the Company’s website, with a replay available afterward. AngioDynamics specializes in products for vascular access, peripheral vascular disease, and oncology, including market-leading ablation systems and vascular access products.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its second quarter financial results for fiscal year 2022 on January 6, 2022, prior to market open. The management will conduct a conference call at 8:00 a.m. ET on the same day to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13725681. The call will also be accessible via webcast on AngioDynamics' website, with a replay available later that day.
AngioDynamics reported fiscal 2022 Q1 results with net sales of $77.0 million, a 9.6% increase year-over-year. Gross margin rose to 52.1%, up 120 basis points. The company reported a GAAP loss per share of $0.18 and an adjusted loss of $0.02. Notably, Med Tech sales surged 68.0% to $17.6 million, driven by the Auryon platform. U.S. sales increased 19.1%, but international sales fell 22.4%. The company raised its FY2022 sales guidance to $310-$315 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its first-quarter fiscal year 2022 financial results on
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 41st Annual Canaccord Genuity Virtual Growth Conference on August 11, 2021, at 9:00 a.m. ET. A live webcast of the presentation will be available on the company’s website and can be replayed afterward. AngioDynamics specializes in minimally invasive medical devices for vascular access and oncology, offering a range of products including ablation systems and vascular access solutions.
AngioDynamics (ANGO) reported Q4 fiscal 2021 net sales of $76.8 million, up 31.7% year-over-year. Endovascular Therapies saw a 72.3% increase, driven by Auryon and AngioVac sales, while oncology sales rose 14.2%. Despite these gains, the company incurred a net loss of $19.5 million, including a $14.0 million write-off. For FY 2021, net sales reached $291.0 million, a 10.2% increase, but net loss was $31.5 million. Looking ahead, FY 2022 guidance estimates net sales of $305 to $310 million and adjusted EPS of $0.00 to $0.05, reflecting ongoing investment in product launches.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
What does AngioDynamics specialize in?
How does AngioDynamics generate its revenue?
What are the key product categories offered by AngioDynamics?
How does AngioDynamics differentiate itself from competitors?
Who are the primary customers of AngioDynamics?
What is the significance of minimally invasive procedures in their product development?
How does the company maintain its industry expertise?
What role does innovation play in AngioDynamics' business model?
